Cardiovascular Complications of Prostate Cancer Therapy
- PDF / 2,011,007 Bytes
- 27 Pages / 595.276 x 790.866 pts Page_size
- 27 Downloads / 244 Views
(2020) 22:69
Cardio-oncology (M Fradley, Section Editor)
Cardiovascular Complications of Prostate Cancer Therapy Courtney M. Campbell, MD, PhD1 Kathleen W. Zhang, MD2 Andrew Collier, MD, FRCPE3 Mark Linch, PhD, FRCP4 Adam C. Calaway, MD5 Lee Ponsky, MD5 Avirup Guha, MD6 Arjun K. Ghosh, MBBS, PhD, FRCP7,8,* Address 1 Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA 2 Division of Cardiology, Cardio-Oncology Center of Excellence, Washington University in St. Louis School of Medicine, St. Louis, MO, USA 3 Diabetes Day Centre, University Hospital, Ayr, UK 4 Department of Oncology, University College London Cancer Institute, London, UK 5 Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA 6 Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, OH, USA 7 Cardio-Oncology Service, Barts Heart Centre, St. Bartholomew’s Hospital West Smithfield, London, UK *,8 Cardio-Oncology Service, Hatter Cardiovascular Institute, University College London Hospital, London, UK Email: [email protected]
* Springer Science+Business Media, LLC, part of Springer Nature 2020
Avirup Guha and Arjun K. Ghosh contributed equally to this work. This article is part of the Topical Collection on Cardio-oncology Keywords Cardio-oncology I Prostate cancer I Gonadotropin-releasing hormone agonist I Gonado-tropin-releasing hormone antagonist I Androgen receptor blockade I Androgen deprivation therapy I Hormone therapy I Cardiovascular disease I Myocardial infarction I Stroke I Hypertension
Abstract Purpose of review With treatment advances, the most common cause of death in prostate cancer patients is cardiovascular disease. Discerning the contribution of prostate cancer treatment on cardiovascular complications versus the natural progression of cardiovascular disease remains an ongoing area of investigation. Evaluating the research and
69
Page 2 of 27
Curr Treat Options Cardio Med
(2020) 22:69
identifying opportunities for further investigation is critical for optimal care of this prostate cancer patient population. Recent findings The degree that hormone therapy contributes to cardiovascular morbidity and mortality remains uncertain with conflicting results from large meta-analyses. Underlying cardiovascular disease or multiple cardiovascular disease risk factors appear to compound the risk of adverse events. Drug-specific cardiotoxicity in prostate cancer treatment has not been fully delineated. Recent studies have suggested the potential for wide-ranging prostate cancer cardiotoxic effects, including atherosclerosis acceleration, myocardial infarction, cardiomyopathy, hypertension, arrhythmias, and stroke along with other thromboembolic diseases. Summary This review provides an overview of prostate cancer treatment, a comprehensive analysis of the literature linking androgen deprivation therapy and cardiovascular disease, a discussion o
Data Loading...
